Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- NUTX +44.6%, PVH +15.7% (also to enter $500 mln ASR), MVST +15.4%, PRGS +7.9% (also names new CEO and COO and files mixed shelf offering), CELC +4.4%
Other news:
- HI +4.7% (completes sale of Majority Stake in Milacron injection molding and extrusion business for $287 mln)
- VCSA +3.9% (Davidson Kempner sent a letter to the Special Committee further enhancing the terms of the prior offers by increasing the cash consideration purchase price to $5.83 per share)
- XRAY +3.7% (files mixed shelf)
- BIGC +3.5% (CTO departing)
- XPEV +3.5% (March deliveries)
- ARDT +2.6% (appoints new COO)
- NIO +2.6% (March deliveries)
- TSSI +1.9% (to delay 10-K filing)
- BTG +1.8% (announces TSX approval for normal course issuer bid)
- AQST +1.4% (topline PK results from its pediatric study and completes the NDA Submission for Anaphylm sublingual film)
- VAL +1.3% ($352 mln contract for drillship)
- INR +1.3% (increases borrowing base under its credit facility)
- APLS +1.1% (FDA has accepted and granted Priority Review designation of the supplemental New Drug Application for EMPAVELI for C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis, which are severe and rare kidney diseases)